This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Do Options Traders Know Something About Catalyst (CPRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.
Implied Volatility Surging for Catalyst (CPRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.
Catalyst Gives Preliminary Firdapse Estimates & Other Updates
by Zacks Equity Research
Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.
Why Is Catalyst (CPRX) Down 5.3% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Focuses on Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst (CPRX) focuses on the development of Firdapse for additional indications.
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.
Catalyst Pharmaceutical (CPRX) Beats Q3 Earnings Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 18.18% and -8.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Catalyst's (CPRX) third-quarter 2019 conference call, investor focus will be on the sales performance of its only marketed drug Firdapse and its label expansion studies.
Investors Can Find Strong Stocks with our First Profit Screen
by Benjamin Rains
Today, we are utilizing our 'First Profit' stock screen to help investors find strong stocks. The idea is to search for companies that just reported their first quarterly profit within the last year...
Learn How to Find Top-Ranked 'Cheap' Stocks Under $10 with this Screener
by Benjamin Rains
Searching for 'cheap' stocks that look poised to climb can be an attractive investment strategy. But investors have to know where and how to find strong stocks trading under $10 a share. So check out this Zacks Stock Screener...
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Implied Volatility Surging for Catalyst (CPRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.
Investors Can Find Big Returns with this First Profit Screen
by Benjamin Rains
We are taking a look at our 'First Profit' stock screen today. The idea is to search for companies that just reported their first quarterly profit within the last year because these firms could prove to be big winners for investors...
Why Is Catalyst (CPRX) Up 23% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Here's How to Find Top-Ranked Stocks Under $10 to Buy
by Benjamin Rains
Here are 5 stocks of the over 30 highly-ranked stocks trading under $10 a share that made it through this week's screen...
Top Ranked Momentum Stocks to Buy for August 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 19th
Will Catalyst Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Catalyst Pharmaceuticals.
Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 233.33% and 50.18%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Catalyst (CPRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Catalyst (CPRX) stock based on the movements in the options market lately.
Catalyst Pharma Focuses on Firdapse Launch & Label Expansion
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) intends to launch Firdapse and expand the label of the same.
Explosive Stocks Under $10
by Benjamin Rains
Let's start the second half of 2019 by searching for "cheap" stocks that look poised to surge...
Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi
by Zacks Equity Research
Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.